World News: 22:16 GMT Thursday 6th December 2018. [EQS Group via SPi World News]
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
December 6, 2018
Fresenius Medical Care gives early preliminary indicative guidance for 2019
- Use of cash currently under evaluation
Fresenius Medical Care, the world's largest provider of dialysis products and services, has decided to update the market early by providing its indicative preliminary assumptions for the business development in 2019.
'With the pending acquisition of NxStage Medical Inc., the corresponding build out of our home dialysis services infrastructure in the United States as well as investments in future growth markets in the Products as well as the Services business such as China, we have an investment year ahead of us,' said Rice Powell, Chief Executive Officer of Fresenius Medical Care. 'We would like to share as an early indication that 2019 will have a clear focus on preparing the company for future sustainable, profitable growth. For 2019, we currently broadly assume solid comparable1 revenue growth and the comparable1 net income to be around the level of FY 2018.'
Fresenius Medical Care is reviewing all factors as part of its budgeting process and plans to publish the guidance for 2019, at the usual level of detail, along with the company's fiscal year 2018 results, which are planned to be released on February 20, 2019.
Fresenius Medical Care intends to reset its 2020 constant currency targets to also reflect the IFRS accounting changes, the divestiture of Sound Inpatient Physicians Holdings and the pending acquisition of NxStage Medical Inc., all as highlighted in the previous quarter. The reset targets are scheduled to be published along with the company's fiscal year 2018 results, which are planned to be released on February 20, 2019.
Fresenius Medical Care will host a conference call on December 7, 2018, at 9:00 a.m. CET / 3:00 a.m. EST. Details will be available on the company's website www.freseniusmedicalcare.com in the 'Investors/Events' section. A replay will be available on the same day of the call.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 329,085 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
Dr. Dominik Heger
SVP & Head of Investor Relations & Corporate Communications
|Company:||Fresenius Medical Care AG & Co. KGaA|
|61352 Bad Homburg|
|Phone:||+49 (0) 6172- 609 2525|
|Fax:||+49 (0) 6172- 609 2301|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange|
|End of News||DGAP News Service|
Read More: http://www.dgap.de/dgap/News/?eqsNewsID=1740283
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.